What Will CMS Do With Avastin In Breast Cancer?

 
• By Ramsey Baghdadi

With FDA’s decision to pull the indication for Avastin in breast cancer, CMS is now waiting and watching for residual use patterns.

Late in the day on June 29, 2011, the Centers for Medicare & Medicaid Services was swamped with reporters’ questions.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers